Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 Popular Ladies' Aromas On the planet - 2Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- 3Investigating the Advantages of a Bank account: A Complete Aide
- 4Two policemen injured at religious youth protest in Jerusalem marking Ahuvia Sandak's death
- 5'Wicked: For Good' was filmed at this surreal National Park in Egypt
- ONE returns to Red Sea with new service
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Family Holiday spots
- 19 Peculiar Films You Shouldn't Watch With Your Mum
- Unfathomable and Entertaining Legal disputes That Surprise everyone
- Blue Origin's next space tourism flight will break new ground for people with disabilities
- Holiday season sees uptick in norovirus cases, according to CDC
- Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
